-
Mashup Score: 0
When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
#Voruciclib with or without venetoclax was generally well tolerated as a treatment for patients with R/R #AML or B-cell malignancies. https://t.co/hTbQbH9GOk